Psychotropic medication in intellectual disability: the central clinical decision
Psychotropic medication can be valuable for a person with intellectual disability when it treats a clearly identified psychiatric condition or another clinically justified target. Antipsychotics can reduce psychotic symptoms and may sometimes be considered for severe behavior that threatens safety, but prescribing them primarily to suppress aggression, agitation, or self-injury requires an especially careful assessment of causes, a defined treatment goal, informed involvement of the person, and a plan for review. Intellectual disability by itself is not an indication for an antipsychotic. The central question is whether the expected, measurable benefit for this individual outweighs adverse effects and the opportunity cost of missing a treatable source of distress. The NICE challenging behavior guideline and the NICE mental health guideline provide complementary clinical frameworks.
In the United States, intellectual disability describes developmental limitations in intellectual functioning and adaptive behavior; in British clinical guidance, the term learning disability often refers to the same population. These terminological differences matter when interpreting the literature. The person may also have autism, epilepsy, communication difficulties, a medical illness, or a separately diagnosable mental disorder. Medication decisions must identify each condition rather than assign every symptom or behavior to the intellectual disability diagnosis. AAIDD describes intellectual disability through intellectual and adaptive functioning and the importance of individualized supports.
This review examines antipsychotics alongside antidepressants, anxiolytics, sedatives, mood-stabilizing medicines, and other psychotropic drugs insofar as they are used in people with intellectual disability. It distinguishes treatment of recognized psychiatric illness from medication used for behaviors that challenge, examines effectiveness and uncertainty, describes safety monitoring and deprescribing, and explains how communication access, positive behavior support, and shared decisions change clinical outcomes.
What psychotropic medication means in this setting
Psychotropic drugs are medicines that affect mood, thinking, perception, attention, arousal, or behavior. Antipsychotics include first-generation medications such as haloperidol and second-generation medications such as risperidone, olanzapine, and aripiprazole. Antidepressants include selective serotonin reuptake inhibitors and other agents used for depressive and anxiety disorders. Benzodiazepines and other sedating drugs may be used for short-term anxiety, acute agitation, or particular sleep-related indications. Medicines commonly described as mood stabilizers include lithium and some antiseizure medications, although indications and adverse effects vary greatly among drugs. Stimulants and selected nonstimulants may be prescribed for co-occurring ADHD where appropriate.
A medicine's pharmacological class does not establish the diagnosis or the target of treatment. An antiseizure medicine prescribed for epilepsy is treating a neurological condition even when it also affects mood. A sedative that makes a person less visibly active has not necessarily relieved anxiety, pain, fear, or environmental overload. A reduction in staff-reported incidents has to be interpreted alongside alertness, communication, autonomy, motor functioning, and quality of life. These are distinct outcomes, and they may move in different directions.
Psychiatric treatment and behavioral prescribing are separate decisions
When a person meets diagnostic criteria for schizophrenia, bipolar disorder, major depressive disorder, an anxiety disorder, or another condition, the relevant disorder-specific treatment guidance remains applicable, with appropriate adaptations to communication and monitoring. The quality of diagnostic assessment matters particularly when the person cannot easily describe internal experiences. NICE NG54 recommends specialist involvement for medication initiation in people with more severe intellectual disability and in children and young people, along with evaluation of other health problems, drug interactions, and the practical feasibility of monitoring.
By contrast, terms such as aggression, noncompliance, screaming, property damage, or behavior that challenges describe observations rather than psychiatric diagnoses. Such behavior can reflect pain, constipation, reflux, untreated dental disease, sensory distress, trauma, inaccessible communication, a disrupted routine, adverse drug effects, or a mental disorder. Its frequency and seriousness demand assessment, but its presence alone does not establish the therapeutic rationale for an antipsychotic. The distinction prevents diagnostic overshadowing and changes which intervention should be tried first.
Why psychotropic prescribing is common
Prescribing is shaped by genuine psychiatric morbidity, co-occurring neurological conditions, the practical demands of support services, limited access to adapted psychological therapies, and the perceived urgency of difficult behavior. Some people need sustained medication for a clearly established illness. Others acquire a prescription during a crisis and remain on it for years without a documented target, a baseline measure, or a reassessment of whether the original problem remains. Medication reconciliation is therefore a scientific and ethical component of ongoing care.
In a population-based UK study using records from 33,016 adults with intellectual disability, Sheehan and colleagues reported that 49% had a psychotropic prescription recorded at cohort entry, compared with 21% with recorded mental illness. During follow-up, antipsychotic initiation was associated with documented behavior that challenges, among other clinical factors. These findings reveal an important mismatch in recording and prescribing; they do not prove that every prescription was inappropriate, because health records can undercapture diagnosis and clinical reasoning. The study remains important for understanding surveillance and service-level risk (Sheehan et al., 2015).
NHS England's STOMP and STAMP programs address inappropriate psychotropic prescribing across childhood and adulthood. Their central principle is appropriate treatment, appropriate dose, regular review, and the shortest duration compatible with effective care. These initiatives are specifically concerned with reducing unnecessary exposure while preserving medicines that have an established benefit. They should not be interpreted as a directive to withdraw effective psychiatric treatment indiscriminately.
Evidence for antipsychotics when behavior challenges
What randomized trials establish
The scientific question is narrower than whether antipsychotics sometimes reduce observable aggression. A useful trial must ask whether the drug adds clinically meaningful benefit beyond placebo or the effects of changing support, for which people, over what duration, and with which harms. In a notable multicenter randomized trial, Tyrer and colleagues assigned 86 nonpsychotic adults with intellectual disability and aggressive challenging behavior to risperidone, haloperidol, or placebo. Placebo recipients did not have worse outcomes than either antipsychotic group in the reported comparisons. The authors argued against routine antipsychotic treatment of aggression in this population (Tyrer et al., 2008).
The trial offers a direct challenge to the assumption that a powerful sedating or dopamine-blocking medicine must be more effective than structured care and nonspecific improvement. Its sample and treatment duration also limit how confidently its results generalize to all ages, etiologies, clinical settings, or exceptionally severe safety crises. A person with a distinct psychotic disorder was outside this trial's principal population. Negative results for routine behavioral prescribing should not be extended to refute antipsychotic treatment of genuine psychotic illness.
A Cochrane review of antipsychotics for challenging behavior found that the randomized evidence then available was inadequate to determine a reliable balance of benefit and harm for adults without an additional mental illness. This review is older than the Tyrer trial and should be read with its evidence-search date in mind. Together they justify a restrained interpretation: effectiveness for undifferentiated behavior that challenges is uncertain, and routine indefinite prescribing is weakly supported.
Why pediatric findings require their own interpretation
Trials involving children with autism, intellectual disability, or mixed neurodevelopmental presentations sometimes report reductions in irritability or serious disruptive behaviors for specific agents. Their populations, outcome scales, regulatory approvals, and time horizons vary. Evidence established in one diagnostic or age group does not automatically become evidence for all children or adults with intellectual disability. Clinicians must distinguish treatment of severe irritability associated with an explicitly defined condition from an attempt to medicate the diagnosis of intellectual disability itself.
In a child or adolescent, benefits must also be weighed against developmental consequences of weight gain, endocrine effects, daytime sedation, movement symptoms, and reduced opportunities for learning. Caregivers and teachers can provide valuable observations, but the person's comfort, engagement, and accessible expression of preferences are essential. A lower count of outbursts alongside worsening participation or sustained somnolence is an ambiguous result, not an automatic therapeutic success.
Evidence grading and its limits
Evidence is established that antipsychotics can cause metabolic, neurological, hormonal, and cardiovascular adverse effects and that effective treatment of a separately diagnosed psychiatric condition can be important. Evidence for antipsychotics as a routine stand-alone intervention for nonspecific challenging behavior in intellectual disability is limited and contested. Preliminary or population-specific findings may justify a carefully monitored individual trial in exceptional circumstances, yet there is no credible scientific basis for equating a behavioral crisis with a permanent pharmacological requirement. Clinical guidelines reflect this distinction rather than reducing decisions to a universal yes or no.
When antipsychotics may be considered for severe behavioral risk
NICE NG11 recommends considering an antipsychotic for behavior that challenges only when psychological or other interventions have not produced change within an agreed period, when treatment of contributing mental or physical conditions has not reduced the behavior, or when risk to the person or others is very severe. It specifies that medication should be offered alongside psychological or other interventions. These are conditional considerations, not evidence that every severe episode needs medication.
The guideline further recommends specialist initiation and monitoring, a clearly defined target behavior, an agreed outcome measure, the minimum effective dose, and one antipsychotic rather than multiple antipsychotics for the same target. Response and side effects should be reviewed after three to four weeks, and medication should be stopped if there is no indication of response at six weeks. As-needed use should be brief and systematically recorded and reviewed. Longer-term continuation demands a renewed clinical justification (NICE NG11).
A clinical emergency may justify immediate measures to prevent serious harm. Even then, the indication, least restrictive option, physical assessment, communication, monitoring, and subsequent review remain important. Acute crisis management and planned long-term prescribing are different decisions. A crisis prescription should not acquire indefinite duration simply because it appeared in a medication chart at discharge or during a residential transition.
Assessment before starting or changing medication
Establish a reliable baseline
A prescribing decision begins by asking what has changed, when it changed, what happened immediately beforehand, and how the change affects the person. Records should describe the specific topography, frequency, severity, duration, and context of the behavior, ideally with observations from multiple environments. A target such as fewer serious injuries is more informative than a vague request for the person to be calmer. Assessment also records what the person values: sleeping well, communicating easily, going to school or work, avoiding pain, maintaining relationships, and participating in daily life.
Psychiatric evaluation requires developmental and medical history, the person's established cognitive and communication profile, and attention to signs of anxiety, depression, mania, psychosis, trauma, or delirium. A change from the individual's usual functioning often carries more diagnostic information than comparison with population norms. Sleep disruption, new avoidance, loss of skills, changes in appetite, altered interests, or uncharacteristic fear may indicate illness even without conventional verbal symptom reports. Diagnostic instruments are aids to clinical judgment, not substitutes for accessible assessment.
Investigate pain, illness, and medication effects
Potential contributors include headache, infection, dental or gastrointestinal pain, constipation, seizures, urinary discomfort, menstrual-related symptoms, medication withdrawal, akathisia, and sleep deprivation. The onset and temporal relationship of each factor should be investigated rather than assumed. Akathisia is especially consequential: an antipsychotic-induced state of intense restlessness can resemble agitation and may lead to further medication escalation if unrecognized. Similarly, sedation can conceal new illness or suppress visible communication.
The assessment should also consider sensory and physical accessibility, trauma histories, environmental predictability, communication barriers, staff consistency, discrimination, and unmet social needs. A person who repeatedly tries to escape an overwhelming environment may require environmental change or communication support. Medication that makes escape less likely without addressing the overwhelming environment may register as a superficial behavioral improvement while leaving the underlying cause intact.
Functional formulation and multidisciplinary collaboration
Functional behavior assessment asks which antecedents and consequences are associated with a behavior and what functions it may serve, such as access to support, escape from discomfort, sensory regulation, or communicating a need. Observational patterns support hypotheses that need to be tested in context. The assessment is most useful when clinical teams combine it with a medical and psychiatric formulation and with information from the person and trusted supporters. The result should lead to specific, feasible changes in support, not merely a label attached to the person.
Collaboration often involves a psychiatrist, primary care clinician, psychologist or behavior specialist, pharmacist, nurse, speech-language pathologist, support workers, and family or chosen supporters when appropriate. Someone must be responsible for identifying the medication's purpose, tracking both benefit and adverse effects, and arranging follow-up across services. Shared care is only safe when monitoring and escalation responsibilities are explicit (NICE NG54).
Risks and adverse effects of antipsychotic treatment
Weight, glucose, lipids, and cardiovascular health
Second-generation antipsychotics vary in their propensity for weight gain, dyslipidemia, insulin resistance, and diabetes. Risk depends on the agent, exposure, underlying health, nutrition, activity, and individual susceptibility. Some first-generation drugs also have major medical and neurological hazards. A person with limited mobility, restricted food choice, poor access to preventive care, or difficulty describing symptoms may experience a particularly high burden. Metabolic monitoring must be designed so that disability-related barriers to testing do not become reasons to ignore risk.
The broader NICE antipsychotic monitoring recommendations include baseline weight and waist circumference, blood pressure and pulse, glucose or HbA1c, lipid measures, prolactin, and movement assessment, followed by scheduled follow-up during treatment. An electrocardiogram is appropriate when indicated by cardiovascular history, examination, medication guidance, or clinical setting. Exact monitoring schedules are adapted to age, agent, indication, and local standards. Good practice combines objective measurements with discussion of energy, appetite, exercise capacity, and daily functioning.
Movement disorders, restlessness, and sedation
Possible neurological adverse effects include drug-induced parkinsonism, tremor, dystonia, akathisia, and tardive dyskinesia. These effects vary by medication and exposure, and some may persist after a drug is stopped. They can undermine mobility, swallowing, expression, and comfort. Staff observations should not confuse a less active person with a healthier person. The team should ask whether the person can move comfortably, eat safely, engage with others, remain awake for meaningful activities, and communicate in familiar ways.
Sedation, dizziness, falls, orthostatic hypotension, and impaired coordination are also relevant. In some people, apparent improvement on incident charts partly reflects reduced alertness or ability to respond. A clinically useful review therefore compares risks and benefits in real-world activity, including mobility, learning opportunities, employment, and relationships. Where a person cannot explain subjective restlessness or emotional dulling, clinicians must use accessible questions and careful observation.
Hormonal, anticholinergic, and other burdens
Certain antipsychotics can raise prolactin, which may cause menstrual changes, sexual dysfunction, galactorrhea, or other endocrine consequences. Anticholinergic effects can contribute to constipation, urinary problems, confusion, and heat intolerance. Drug-specific risks also include QT prolongation and seizure-threshold effects, which are important when epilepsy or interacting medication is present. Potential severe reactions, although uncommon, require urgent assessment when symptoms suggest a medical emergency. Adverse effects may be underreported when diagnostic overshadowing makes clinicians attribute new symptoms to disability instead of treatment.
Antidepressants, anxiolytics, mood stabilizers, and stimulants
Antidepressants may be considered for a properly assessed depressive or anxiety disorder using the evidence and guidance for that disorder. Baseline mood, activity, sleep, appetite, distress, functioning, and safety should be recorded in accessible ways. Monitoring includes activation, agitation, gastrointestinal effects, sleep changes, interactions, and emergence of other concerning symptoms. An observable reduction in repetitive behavior does not, by itself, establish that depression or an anxiety disorder was present. Psychotherapy and environmental adaptations may be essential elements of care even when medication is used.
Benzodiazepines and sedative-hypnotics can have specific short-term indications, but tolerance, dependence, withdrawal, falls, respiratory effects, and paradoxical disinhibition require consideration. Their intermittent use can be difficult to interpret if the administered dose, reason, and response are poorly documented. Long-term prescribing for an ill-defined behavioral target warrants review. Abrupt changes in benzodiazepine use can cause serious withdrawal symptoms, including seizures, so any reduction requires an individualized clinician-led plan.
Lithium and antiseizure medicines used for mood stabilization require indication-specific assessment and laboratory or clinical monitoring. Epilepsy treatment can be indispensable in a person with intellectual disability; stopping an antiseizure medication without understanding its neurological indication can provoke seizures. Some agents carry renal, thyroid, hepatic, hematologic, reproductive, or interaction risks. Medication choices and pregnancy-related safety requirements evolve, so prescribers should consult current regulator and product guidance rather than infer safety from a medicine's familiar use in behavioral practice.
Stimulant or nonstimulant treatment for co-occurring ADHD is a separate diagnostic and therapeutic pathway. Symptoms of inattention, motor activity, or impulsivity require interpretation against developmental expectations and the person's communication and environmental context. Treatment response should be judged through meaningful functioning and tolerability, with cardiovascular, sleep, appetite, and mood monitoring as appropriate. Evidence from ADHD or other psychiatric disorders should not be used as proof that a drug treats intellectual disability itself.
Polypharmacy, prescribing cascades, and medicine reconciliation
Polypharmacy is clinically justified in some situations, such as co-occurring epilepsy and a severe mood disorder. Its risks rise when multiple drugs have overlapping sedative, anticholinergic, metabolic, cardiovascular, or neurological effects. A common pattern is adding one medicine for a symptom caused by another, then adding a third to manage the first two drugs' consequences. This prescribing cascade can make the original indication difficult to reconstruct. A medication review should establish a timeline of initiation, dose changes, measurable responses, side effects, and changes in the person's life.
For every current drug, the team should identify the diagnosed condition or precise target symptom, the evidence supporting use, the date and reason of initiation, the observed outcome, adverse effects, responsible prescriber, review interval, and intended duration. This should include as-needed medicines, over-the-counter agents, and drugs prescribed by neurology or other specialties. A person who has moved between child and adult services or between residential settings may have a particularly fragmented history. The goal is one coherent treatment plan that balances all of the person's health conditions.
NICE NG54 advises consideration of reduction or discontinuation of long-term antipsychotics in people without psychotic symptoms, with clinical review after changes and annual documentation of the reasons for continuation when the medicine is not reduced or stopped. It also advises changing one drug at a time when switching medicines to make withdrawal and interactions easier to interpret. This is a structured clinical process rather than a numerical target for how many prescriptions must be eliminated.
Monitoring: how to tell whether treatment helps
A meaningful medication trial combines at least three kinds of outcome: the identified psychiatric symptom or safety target, adverse effects, and the person's overall functioning and quality of life. A chart that records only incidents may reward sedation. A chart that records only side effects may overlook clinically serious deterioration. Both types of evidence are needed, alongside the person's perspective and support network's observations. Measures should be chosen before initiating treatment to reduce selective interpretation of improvement.
The first review addresses the target behavior or psychiatric syndrome, medication use, adherence, dose and timing, observable adverse reactions, sleep, appetite, physical symptoms, participation, and changes in the environment. For antipsychotics considered specifically for behavior that challenges, NICE NG11 specifies clinical review at three to four weeks and discontinuation when no response is evident at six weeks. The companion NICE quality standard describes a multidisciplinary review at twelve weeks and at least every six months thereafter. Earlier attention is warranted when adverse reactions emerge or the person deteriorates.
Monitoring must be accessible. Blood draws, weighing, and physical examinations may require adjustments for sensory needs, processing time, consent, and physical access. Explanations can use short sentences, pictures, easy-read leaflets, interpreters, or augmentative communication. Supporters can help report symptoms without replacing the person's own perspective. Decisions about laboratory testing should acknowledge that refusal or distress may arise from previous medical trauma; planning and accommodations may make safe monitoring feasible.
Deprescribing and safe discontinuation
Deprescribing is the supervised process of reducing or stopping a medicine whose current risks, lack of benefit, or changed indication warrant review. It begins by determining why the drug was started, whether its original target remains, whether an active psychiatric illness is being treated, which other conditions are present, and what support is in place. Sudden discontinuation can cause withdrawal phenomena or recurrence of an adequately treated illness; it can also obscure which change led to deterioration. The approach is necessarily drug-specific and individualized.
A 2023 systematic review identified 54 studies of deprescribing psychotropic medication used for behaviors that challenge in people with intellectual disabilities. The synthesis found that dose reduction or discontinuation was sometimes feasible, with both positive and negative outcomes reported. Many studies were small, observational, short-term, or methodologically heterogeneous. The review noted that interdisciplinary models and planned support were associated with more favorable outcomes, but the design of available studies does not establish a universally effective withdrawal protocol.
Clinical monitoring during reduction should consider the recurrence of the original psychiatric or behavioral target, emerging insomnia or anxiety, movement disorders, withdrawal effects, pain, and changes in support. A transient deterioration may have several explanations, including physiological withdrawal, underlying illness, environmental changes, or loss of a genuinely beneficial treatment. If severe risk recurs, clinicians should reassess rather than assume that every symptom proves permanent medication dependence. There is no generic timetable or safe one-size-fits-all dose reduction for antipsychotics, benzodiazepines, lithium, antidepressants, or antiseizure drugs.
People and supporters should have a written plan for whom to contact, which changes require urgent assessment, how follow-up will occur, and how communication supports and behavioral interventions will be maintained. Collaborative, gradual medication review respects the possibility that some people will benefit from continued treatment while others can reduce unnecessary exposure. Never stop a prescribed psychotropic, particularly a benzodiazepine, antiepileptic, or antipsychotic used for serious mental illness, without appropriate clinical supervision.
Nonpharmacological treatment and positive behavior support
Behavior that challenges often communicates a mismatch between a person's needs and the demands or resources of an environment. Functional assessment can identify situations that precede distress and patterns that sustain it, enabling changes in routines, sensory conditions, communication, social contact, or access to preferred activities. Positive behavior support integrates person-centered planning with prevention, skills teaching, environmental change, and ethical responses to crises. The objectives include safety and meaningful participation, not just lower behavior counts.
Treating pain, constipation, insomnia, seizures, or other health conditions may reduce behavior without requiring psychiatric medication. Adapted psychological treatments can also address mental disorders, with communication adjustments, visual supports, simplified materials, shorter or more flexible sessions, repetition, and involvement of trusted supporters when appropriate. For severe safety risks, support plans need operational details and trained responders; vague instructions to use behavioral strategies provide insufficient protection. Accessible care and clinical treatment should work together.
Evidence for particular nonpharmacological interventions also varies with program fidelity, clinical complexity, outcome measures, and study design. A favorable result in one setting cannot guarantee replication everywhere, and poorly implemented support can fail. Nonetheless, the need to assess causes and improve the environment does not disappear when a medicine is considered. NICE's recommendation that antipsychotics for behavior that challenges accompany psychological or other interventions reflects this integrated approach (NICE NG11).
Choice, capacity, consent, and safeguards
A person's intellectual disability diagnosis does not determine their ability to make every medical decision. Decision-making ability depends on the particular choice, how information is presented, the supports available, and the applicable legal framework. An accessible explanation should cover why the medicine is proposed, what improvement is hoped for, common and serious adverse effects, alternatives, how the team will measure response, and the plan for continuing or stopping. Where another decision-maker has a lawful role, the person's wishes and participation still matter.
Medication used primarily to make a person quieter, easier to supervise, or more convenient for an institution raises concerns about restrictive practice. When prescribing affects alertness, mobility, sexuality, learning, or independence, the ethical stakes extend beyond incident reduction. Quality of life, dignity, and freedom from avoidable restraint are legitimate clinical outcomes. Safeguarding systems should review patterns of repeated as-needed sedation, missing indications, absent monitoring, and a lack of access to psychological, communication, or social support.
Families and direct-support workers contribute essential longitudinal observations, but they may have different pressures and risk tolerances. Clinicians should elicit the person's own preferences with accessible communication and avoid assuming that carers' convenience captures treatment benefit. Risk assessment can recognize serious aggression or injury without defining the person by the behavior. Transparent documentation enables future prescribers to distinguish a necessary therapeutic trial from inherited prescribing habits.
Differences across childhood, adulthood, and aging
In childhood, developmental change, learning opportunities, school participation, and family functioning make sedation and metabolic effects particularly consequential. Diagnosis may evolve as communication and adaptive skills develop. In adolescence, transitions between services are points where medication histories can become fragmented and behavioral descriptions replace clinical formulations. Transfer plans should carry forward the indication, outcome data, metabolic monitoring, and decisions about future review, not just the current prescription list.
Adults may experience changes in employment, relationships, housing, trauma exposure, physical health, and access to care that alter the context of behavior and psychiatric symptoms. A medicine that was useful during a short crisis may no longer have the same risk-benefit balance after community support improves. Conversely, an adult with recurrent psychosis or severe mood episodes may benefit from maintenance treatment. Clinical review must distinguish these pathways and preserve continuity of effective care.
In older adults, frailty, falls, polypharmacy, sleep disorders, sensory loss, and dementia-related changes may increase medication-related vulnerability. New behavioral symptoms warrant investigation relative to the individual's longstanding functioning. Treatments for dementia-related distress and other conditions follow their own risk-benefit frameworks. Age, underlying syndromes, and co-occurring illnesses should inform monitoring rather than lead automatically to either escalation or withdrawal.
Research limitations and unanswered questions
The literature combines heterogeneous groups: people with mild and profound intellectual disability, autistic and nonautistic people, different genetic syndromes, varied mental health diagnoses, children and adults, and institutional and community settings. Some trials exclude those at greatest medical or behavioral risk. Outcomes may rely on staff-reported behavior scales that cannot fully measure emotional well-being, autonomy, or subjective experience. Follow-up is often too short to reveal long-term endocrine, metabolic, neurological, and participation effects.
Comparative effectiveness research needs clearer distinctions between target diagnoses and observed behaviors, baseline functional formulations, drug and dose exposure, and concurrent support interventions. Better trials should report individual outcomes and adverse effects, access to communication, quality of life, and the experiences of people with intellectual disability. Deprescribing studies need longer follow-up and transparent definitions of withdrawal symptoms, relapse, replacement treatments, and meaningful community outcomes. The best clinical judgment uses the strongest available evidence while acknowledging where evidence remains limited.
The generalizable conclusion is a decision standard: identify a justified indication; assess treatable contributors; choose a measurable therapeutic target; involve the person; use appropriate psychosocial and environmental supports; weigh drug-specific harms; monitor systematically; and reassess the need for treatment. That standard can support both appropriate prescribing and safe reduction of unnecessary medication.
Frequently asked questions
Does intellectual disability itself require antipsychotic medication?
No. Intellectual disability is a developmental condition characterized by limitations in intellectual and adaptive functioning. Medication may be indicated for a co-occurring psychiatric disorder or, under tightly defined clinical circumstances, for severe safety-threatening behavior after appropriate assessment and with accompanying nonpharmacological treatment. The intellectual disability diagnosis alone does not establish a medication indication (AAIDD; NICE NG11).
Can risperidone or another antipsychotic treat aggression in every person with intellectual disability?
The response varies, and routine treatment of undifferentiated aggression has limited supporting evidence. An important randomized trial found no superiority of risperidone or haloperidol over placebo for aggressive challenging behavior in nonpsychotic adults with intellectual disability. A specialist may still judge a carefully monitored trial appropriate in selected severe circumstances under relevant clinical guidelines (Tyrer et al., 2008; NICE NG11).
How quickly should an antipsychotic prescribed for challenging behavior be reviewed?
The NICE NG11 pathway calls for assessment of response and adverse effects after three to four weeks and stopping the medicine when no benefit is evident at six weeks. The NICE quality standard calls for a multidisciplinary review at twelve weeks and at least every six months thereafter. These recommendations concern a specific prescribing context; other psychiatric indications can require different schedules (NICE NG11; NICE QS101).
Can someone stop psychotropic medication after taking it for years?
Many people can have treatment safely reviewed, and some can reduce or discontinue medicines that are no longer justified. Outcomes are variable; withdrawal, recurrence of psychiatric illness, or worsening behavior may occur. A clinician-led plan must account for the specific drug, its indication, duration, interactions, health status, and access to other support. Abrupt self-directed stopping may be dangerous (deprescribing systematic review).
What should a family member or support worker ask at a medication review?
Useful questions include what the medication treats; how the team knows it helps; which adverse effects are being monitored; whether pain, illness, anxiety, or environmental factors were assessed; which nonpharmacological supports are provided; and when the indication and dose will next be reassessed. The person taking the medicine should participate with their preferred communication supports. NHS England provides STOMP and STAMP materials for collaborative reviews.
Related Articles
Cluster Intellectual and Developmental Disabilities — Scientific overview of diagnosis, adaptive functioning, support systems, and lifespan perspectives.
Mental Health Problems in People With Intellectual Disability: Recognition and Care — Recognizing psychiatric illness and adapting mental health assessment and treatment.
Diagnostic Overshadowing in Intellectual Disability: How Conditions Are Missed — Preventing missed medical and psychiatric causes of behavioral change.
Functional Behavior Assessment in Intellectual Disability: Methods and Examples — Building functional explanations before selecting interventions.
Positive Behavior Support for Intellectual Disability: Principles and Evidence — Designing supportive environments and measurable, person-centered care.
Self-Injurious Behavior in Intellectual Disability: Risk Assessment and Support — Differentiating risk, distress, and intervention pathways.
Adapted Cognitive Behavioral Therapy for Intellectual Disability — Evidence and adaptations of CBT interventions for people with ID.
Sleep Problems in Intellectual Disability: Causes, Assessment, and Care — Sleep complaints and care considerations for people with ID.
References
Adams, D., Hastings, R. P., Maidment, I., Shah, C., and Langdon, P. E. (2023). Deprescribing psychotropic medicines for behaviours that challenge in people with intellectual disabilities: A systematic review. BMC Psychiatry, 23, 202. https://doi.org/10.1186/s12888-022-04479-w.
American Association on Intellectual and Developmental Disabilities. (n.d.). Defining criteria for intellectual disability. AAIDD official definition.
Brylewski, J., and Duggan, L. (2004). Antipsychotic medication for challenging behaviour in people with learning disability. Cochrane Database of Systematic Reviews, CD000377. Cochrane evidence review.
National Health Service England. (n.d.). Stopping over medication of people with a learning disability and autistic people (STOMP) and supporting treatment and appropriate medication in paediatrics (STAMP). NHS England official program.
National Institute for Health and Care Excellence. (2014, amended 2021). Psychosis and schizophrenia in adults: Prevention and management (CG178). Antipsychotic physical health monitoring.
National Institute for Health and Care Excellence. (2015). Challenging behaviour and learning disabilities: Prevention and interventions for people with learning disabilities whose behaviour challenges (NG11). Official guidance.
National Institute for Health and Care Excellence. (2015, updated 2019). Learning disability: Behaviour that challenges (QS101), quality statement 12. Medication review recommendations.
National Institute for Health and Care Excellence. (2016). Mental health problems in people with learning disabilities: Prevention, assessment and management (NG54). Official guidance.
Sheehan, R., Hassiotis, A., Walters, K., Osborn, D., Strydom, A., and Horsfall, L. (2015). Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. BMJ, 351, h4326. https://doi.org/10.1136/bmj.h4326.
Tyrer, P., Oliver-Africano, P. C., Ahmed, Z., et al. (2008). Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: A randomised controlled trial. The Lancet, 371(9606), 57–63. https://doi.org/10.1016/S0140-6736(08)60072-0.